Physician
SMSJ Tucson Holdings LLC
SMSJ Tucson Holdings LLC was paid $28.93M by Medicaid between Jan 2018 and Dec 2024, across 267 billing codes. Its largest line is 99284, emergency room visit (serious) — 24% of everything it billed.
33Billing provider infoSMSJ TUCSON HOLDINGS LLC
TUCSON, AZ 85711
TUCSON, AZ 85711
33aNPI1538535158assigned 08/18/2015
33bProvider typeDiagnostic Radiology Physician
28Total paid$28.93M
24GClaims832,261
24DCodes billed267
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Diagnostic Radiology Physician providers in Arizona
Rank by total paid#3 of 132
Median peer was paid$6K
This provider vs. median4,475×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 152,039 | $4.27M | |
| 2019 | 148,768 | $4.24M | |
| 2020 | 114,214 | $4.13M | |
| 2021 | 129,216 | $4.37M | |
| 2022 | 121,987 | $4.36M | |
| 2023 | 92,244 | $4.15M | |
| 2024incomplete | 73,793 | $3.41M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 31,386 | 28,048 | $7.02M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 27,911 | 25,358 | $5.38M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 11% | 6,159 | 5,610 | $3.06M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.7% | 13,292 | 11,986 | $2.50M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.1% | 8,496 | 7,609 | $1.47M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.9% | 2,634 | 2,420 | $1.12M |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.4% | 3,407 | 3,077 | $698K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 2.1% | 2,868 | 2,580 | $615K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 12,789 | 4,549 | $594K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.9% | 1,486 | 1,355 | $552K |
| G0378 | Hospital observation service, per hour | 1.9% | 7,529 | 4,092 | $547K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 15,901 | 12,269 | $520K |
255 more codes
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.4% | 388 | $410K |
| C1781 | Mesh (implantable) | 1.4% | 247 | $399K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 4,421 | $374K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.3% | 7,370 | $371K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 3,942 | $319K |
| 59025 | Fetal non-stress test | 1.0% | 2,276 | $291K |
| 97162 | <1% | 2,234 | $189K | |
| 70486 | <1% | 931 | $134K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,423 | $132K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 114 | $124K |
| 72131 | <1% | 1,538 | $114K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,224 | $106K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,957 | $106K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,631 | $104K |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 947 | $100K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 529 | $83K |
| 67040 | <1% | 48 | $79K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 224 | $76K |
| 36224 | <1% | 12 | $74K | |
| 70498 | <1% | 304 | $63K | |
| 73564 | <1% | 1,599 | $61K | |
| 47562 | <1% | 13 | $61K | |
| 58571 | <1% | 14 | $58K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 40 | $56K |
| 97116 | <1% | 3,797 | $54K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 560 | $53K |
| 97597 | <1% | 870 | $52K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,305 | $49K |
| 93798 | <1% | 560 | $44K | |
| 95812 | <1% | 240 | $42K | |
| 73030 | <1% | 1,036 | $38K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,540 | $36K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 86 | $34K |
| 67113 | <1% | 13 | $30K | |
| 97161 | <1% | 1,206 | $30K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 400 | $27K |
| 10060 | <1% | 116 | $25K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,398 | $23K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,287 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,709 | $21K |
| 36410 | <1% | 511 | $21K | |
| 72128 | <1% | 1,114 | $21K | |
| 12001 | <1% | 110 | $19K | |
| 93971 | <1% | 1,092 | $19K | |
| 97113 | <1% | 726 | $18K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 603 | $17K |
| 80053 | Comprehensive metabolic panel | <1% | 45,726 | $17K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,665 | $15K |
| 87070 | <1% | 3,380 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 15,170 | $13K |
| 71250 | <1% | 166 | $11K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,621 | $9K |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 27 | $9K |
| 29125 | <1% | 60 | $9K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 118 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,943 | $8K |
| 73130 | <1% | 1,223 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,217 | $8K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $8K |
| 96376 | <1% | 5,181 | $7K | |
| 73630 | <1% | 1,181 | $7K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,428 | $7K |
| 95811 | <1% | 15 | $7K | |
| 97166 | <1% | 145 | $6K | |
| 12002 | <1% | 56 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,152 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,059 | $5K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 227 | $5K |
| 73110 | <1% | 366 | $5K | |
| 84484 | <1% | 15,242 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,301 | $4K |
| 88313 | <1% | 769 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 341 | $4K |
| 92540 | <1% | 12 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 24 | $3K |
| 76801 | <1% | 804 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 18,003 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,875 | $3K |
| 97163 | <1% | 15 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 49,843 | $2K |
| 36430 | <1% | 28 | $2K | |
| 80320 | <1% | 3,887 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 134 | $2K |
| 73610 | <1% | 933 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,001 | $2K |
| 80143 | <1% | 1,102 | $2K | |
| 84702 | <1% | 2,809 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 927 | $2K |
| 86850 | <1% | 3,573 | $1K | |
| 87040 | <1% | 2,563 | $1K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 17 | $1K |
| 81002 | <1% | 5,012 | $1K | |
| 72100 | <1% | 57 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,701 | $1K |
| C1769 | Guide wire | <1% | 1,601 | $1K |
| 89060 | <1% | 145 | $947.72 | |
| 88307 | <1% | 621 | $894.42 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,013 | $779.80 |
| 81001 | <1% | 19,989 | $725.55 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,034 | $691.66 |
| 82948 | <1% | 11,880 | $665.43 | |
| 87088 | <1% | 5,948 | $583.43 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 123 | $488.18 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,338 | $482.82 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,844 | $358.57 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12 | $348.84 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 10,455 | $337.05 |
| 81025 | <1% | 11,605 | $326.59 | |
| 82803 | <1% | 161 | $302.69 | |
| 83735 | <1% | 24,980 | $287.08 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,343 | $255.84 |
| 87073 | <1% | 1,061 | $238.94 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,796 | $233.09 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,919 | $224.34 |
| 83690 | <1% | 12,420 | $213.31 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,834 | $199.27 |
| 76830 | Ultrasound, transvaginal | <1% | 288 | $185.96 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,393 | $162.89 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,448 | $161.16 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,781 | $160.80 |
| 84132 | <1% | 1,128 | $155.45 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $148.61 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,121 | $148.22 |
| 83605 | <1% | 5,378 | $144.57 | |
| 83880 | <1% | 3,675 | $124.00 | |
| 87634 | <1% | 505 | $121.71 | |
| 85610 | <1% | 10,587 | $118.86 | |
| 97165 | <1% | 13 | $116.58 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,621 | $114.20 |
| 86900 | <1% | 4,193 | $114.15 | |
| 90715 | <1% | 1,924 | $113.70 | |
| 85014 | <1% | 2,482 | $98.17 | |
| 85379 | <1% | 2,688 | $78.87 | |
| 93017 | <1% | 114 | $75.31 | |
| 87210 | <1% | 742 | $70.56 | |
| 87186 | <1% | 2,456 | $67.46 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 201 | $66.97 |
| 80061 | Lipid panel | <1% | 1,040 | $64.03 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,924 | $63.57 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,453 | $57.76 |
| 86901 | <1% | 4,193 | $55.77 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 209 | $52.06 |
| 85730 | <1% | 5,986 | $44.31 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,791 | $42.99 |
| 87077 | <1% | 1,980 | $41.36 | |
| 84703 | <1% | 2,994 | $41.30 | |
| 87430 | <1% | 1,449 | $41.18 | |
| 81003 | <1% | 3,653 | $32.72 | |
| 85027 | <1% | 3,786 | $31.45 | |
| 87205 | <1% | 1,897 | $31.08 | |
| 87807 | <1% | 99 | $30.17 | |
| 36416 | <1% | 1,886 | $28.75 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,111 | $28.12 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,969 | $24.80 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,797 | $24.34 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 780 | $24.26 |
| 82272 | <1% | 68 | $23.15 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 937 | $21.94 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,945 | $21.28 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,243 | $19.71 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 961 | $19.20 |
| 87147 | <1% | 646 | $17.08 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,550 | $16.37 |
| 94760 | <1% | 3,948 | $16.04 | |
| 80047 | <1% | 630 | $14.87 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 985 | $14.22 |
| 73502 | <1% | 113 | $12.48 | |
| 94664 | <1% | 281 | $12.34 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,353 | $11.88 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 274 | $11.74 |
| 82550 | <1% | 2,176 | $5.80 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,354 | $4.59 |
| 84100 | <1% | 2,532 | $2.70 | |
| 85651 | <1% | 528 | $2.37 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 406 | $1.20 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 764 | $0.67 |
| A9270 | Non-covered item or service | <1% | 27,636 | $0.35 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 315 | $0.00 |
| 84550 | 0% | 248 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 435 | $0.00 |
| 82565 | 0% | 864 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 1,393 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 80 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 1,724 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 74 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 388 | $0.00 |
| 82140 | 0% | 92 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,430 | $0.00 |
| 86923 | 0% | 40 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,022 | $0.00 |
| 73590 | 0% | 72 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 34 | $0.00 |
| 96367 | 0% | 45 | $0.00 | |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 96 | $0.00 |
| 84520 | 0% | 182 | $0.00 | |
| 84450 | 0% | 73 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 312 | $0.00 |
| 36600 | 0% | 63 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 20 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 100 | $0.00 |
| 82248 | 0% | 133 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 51 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 70 | $0.00 |
| 95957 | 0% | 159 | $0.00 | |
| 73080 | 0% | 72 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 14 | $0.00 |
| 74018 | 0% | 15 | $0.00 | |
| 87324 | 0% | 17 | $0.00 | |
| 73140 | 0% | 26 | $0.00 | |
| 99152 | 0% | 31 | $0.00 | |
| 85384 | 0% | 13 | $0.00 | |
| 82010 | 0% | 30 | $0.00 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 0% | 22 | $0.00 |
| 84460 | 0% | 73 | $0.00 | |
| 82374 | 0% | 17 | $0.00 | |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 12 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 16 | $0.00 |
| J3470 | Injection, hyaluronidase, up to 150 units | 0% | 1,581 | $0.00 |
| 88304 | 0% | 1,005 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 1,062 | $0.00 |
| 88342 | 0% | 1,074 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 402 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,553 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 68 | $0.00 |
| 85018 | 0% | 141 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 135 | $0.00 |
| 99406 | 0% | 25 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 245 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 599 | $0.00 |
| 82150 | 0% | 31 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 85 | $0.00 |
| 93797 | 0% | 63 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 102 | $0.00 |
| 87015 | 0% | 165 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 68 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 101 | $0.00 |
| 83986 | 0% | 113 | $0.00 | |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 83 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 208 | $0.00 |
| 87490 | 0% | 113 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 102 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 21 | $0.00 |
| 86140 | 0% | 61 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 40 | $0.00 |
| 72170 | 0% | 63 | $0.00 | |
| 86592 | 0% | 26 | $0.00 | |
| 36226 | 0% | 12 | $0.00 | |
| 70496 | 0% | 43 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 18 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 19 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 17 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 28 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCORMIER, CRISTIAN (CFO)
| Provider | Location | Paid |
|---|---|---|
| SMSJ Tucson Holdings LLC | Tucson, AZ | $29.82M |
| SMSJ Tucson Holdings, LLC | Tucson, AZ | $2.95M |
| SMSJ Tucson Holdings LLC | Tucson, AZ | $2.43M |
| SMSJ Tucson Holdings, LLC | Tucson, AZ | $25K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.